The Prognostic Utility of MRI in Clinically Isolated Syndrome: A Literature Review

REFERENCES

1. 1.↵
   2. Miller DH,
   3. Chard DT,
   4. Ciccarelli O

   . Clinically isolated syndromes. Lancet Neurol 2012;11:157–69

   CrossRefPubMedWeb of Science
2. 2.↵
   2. Miller DH,
   3. Weinshenker BG,
   4. Filippi M, et al

   . Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler 2008;14:1157–74

   Abstract/FREE Full Text
3. 3.↵
   2. Tozer DJ,
   3. Marongiu G,
   4. Swanton JK, et al

   . Texture analysis of magnetization transfer maps from patients with clinically isolated syndrome and multiple sclerosis. J Magn Reson Imaging 2009;30:506–13

   CrossRefPubMedWeb of Science
4. 4.↵
   2. Summers M,
   3. Swanton J,
   4. Fernando K, et al

   . Cognitive impairment in multiple sclerosis can be predicted by imaging early in the disease. J Neurol Neurosurg Psychiatry 2008;79:955–58

   Abstract/FREE Full Text
5. 5.↵
   2. Patrucco L,
   3. Rojas JI,
   4. Miguez JS, et al

   . Application of the McDonald 2010 criteria for the diagnosis of multiple sclerosis in an Argentinean cohort of patients with clinically isolated syndromes. Mult Scler 2013;19:1297–301

   Abstract/FREE Full Text
6. 6.↵
   2. Brex PA,
   3. Ciccarelli O,
   4. O'Riordan JI, et al

   . A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002;346:158–64

   CrossRefPubMedWeb of Science
7. 7.↵
   2. Fisniku LK,
   3. Brex PA,
   4. Altmann DR, et al

   . Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008;131:808–17

   Abstract/FREE Full Text
8. 8.↵
   2. Brex PA,
   3. O'Riordan JI,
   4. Miszkiel KA, et al

   . Multisequence MRI in clinically isolated syndromes and the early development of MS. Neurology 1999;53:1184–90

   CrossRef
9. 9.↵
   2. Tintoré M,
   3. Rovira A,
   4. Río J, et al

   . Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology 2006;67:968–72

   CrossRef
10. 10.↵
    2. Alroughani R,
    3. Al Hashel J,
    4. Lamdhade S, et al

    . Predictors of conversion to multiple sclerosis in patients with clinical isolated syndrome using the 2010 revised McDonald criteria. ISRN Neurol 2012;2012:792192

    PubMed
11. 11.↵
    2. Dalton CM,
    3. Brex PA,
    4. Jenkins R, et al

    . Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis. J Neurol Neurosurg Psychiatry 2002;73:141–47

    Abstract/FREE Full Text
12. 12.↵
    2. Moraal B,
    3. Pohl C,
    4. Uitdehaag BM, et al

    . Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT study. Arch Neurol 2009;66:1345–52

    CrossRefPubMedWeb of Science
13. 13.↵
    2. Brex PA,
    3. Miszkiel KA,
    4. O'Riordan JI, et al

    . Assessing the risk of early multiple sclerosis in patients with clinically isolated syndromes: the role of a follow up MRI. J Neurol Neurosurg Psychiatry 2001;70:390–93

    Abstract/FREE Full Text
14. 14.↵
    2. Pestalozza IF,
    3. Pozzilli C,
    4. Di Legge S, et al

    . Monthly brain magnetic resonance imaging scans in patients with clinically isolated syndrome. Mult Scler 2005;11:390–94

    Abstract/FREE Full Text
15. 15.↵
    2. Dalton CM,
    3. Brex PA,
    4. Miszkiel KA, et al

    . Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis. Ann Neurol 2002;52:47–53

    CrossRefPubMedWeb of Science
16. 16.↵
    2. Zivadinov R,
    3. Havrdová E,
    4. Bergsland N, et al

    . Thalamic atrophy is associated with development of clinically definite multiple sclerosis. Radiology 2013;268:831–41

    CrossRefPubMed
17. 17.↵
    2. Brex PA,
    3. Leary SM,
    4. Plant GT, et al

    . Magnetization transfer imaging in patients with clinically isolated syndromes suggestive of multiple sclerosis. AJNR Am J Neuroradiol 2001;22:947–51

    Abstract/FREE Full Text
18. 18.↵
    2. Zhang WY,
    3. Hou YL

    . Prognostic value of magnetic resonance imaging in patients with clinically isolated syndrome conversion to multiple sclerosis: a meta-analysis. Neurol India 2013;61:231–38

    CrossRefPubMed
19. 19.↵
    Predictors of short-term disease activity following a first clinical demyelinating event: analysis of the CHAMPS placebo group. Mult Scler 2002;8:405–09

    Abstract/FREE Full Text
20. 20.↵
    CHAMPS Study Group. MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group. Neurology 2002;59:998–1005

    CrossRef
21. 21.↵
    Baseline MRI characteristics of patients at high risk for multiple sclerosis: results from the CHAMPS trial. Controlled high-risk subjects Avonex multiple sclerosis prevention study. Mult Scler 2002;8:330–38

    Abstract/FREE Full Text
22. 22.↵
    2. Kalincik T,
    3. Vaneckova M,
    4. Tyblova M, et al

    . Volumetric MRI markers and predictors of disease activity in early multiple sclerosis: a longitudinal cohort study. PloS One 2012;7:e50101

    CrossRefPubMedWeb of Science
23. 23.↵
    2. Polman C,
    3. Kappos L,
    4. Freedman MS, et al

    . Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b. J Neurol 2008;255:480–87

    CrossRefPubMedWeb of Science
24. 24.↵
    2. Rovira A,
    3. Swanton J,
    4. Tintore M, et al

    . A single, early magnetic resonance imaging study in the diagnosis of multiple sclerosis. Arch Neurol 2009;66:587–92

    CrossRefPubMedWeb of Science
25. 25.↵
    2. Nielsen JM,
    3. Pohl C,
    4. Polman CH, et al

    . MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome. BMC Neurol 2009;9:19

    CrossRefPubMed
26. 26.↵
    2. Kurtzke JF

    . Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444–52

    CrossRefPubMed
27. 27.↵
    2. Whitaker JN,
    3. McFarland HF,
    4. Rudge P, et al

    . Outcomes assessment in multiple sclerosis clinical trials: a critical analysis. Mult Scler 1995;1:37–47

    Abstract/FREE Full Text
28. 28.↵
    2. Rudick R,
    3. Antel J,
    4. Confavreux C, et al

    . Clinical outcomes assessment in multiple sclerosis. Ann Neurol 1996;40:469–79

    CrossRefPubMedWeb of Science
29. 29.↵
    2. Di Filippo M,
    3. Anderson VM,
    4. Altmann DR, et al

    . Brain atrophy and lesion load measures over 1 year relate to clinical status after 6 years in patients with clinically isolated syndromes. J Neurol Neurosurg Psychiatry 2010;81:204–08

    Abstract/FREE Full Text
30. 30.↵
    2. Kincses ZT,
    3. Ropele S,
    4. Jenkinson M, et al

    . Lesion probability mapping to explain clinical deficits and cognitive performance in multiple sclerosis. Mult Scler 2011;17:681–89

    Abstract/FREE Full Text
31. 31.↵
    2. Ceccarelli A,
    3. Rocca MA,
    4. Pagani E, et al

    . A voxel-based morphometry study of grey matter loss in MS patients with different clinical phenotypes. NeuroImage 2008;42:315–22

    CrossRefPubMedWeb of Science
32. 32.↵
    2. Brex PA,
    3. Gomez-Anson B,
    4. Parker GJ, et al

    . Proton MR spectroscopy in clinically isolated syndromes suggestive of multiple sclerosis. J Neurol Sci 1999;166:16–22

    CrossRefPubMedWeb of Science
33. 33.↵
    2. Jafari N,
    3. Kreft KL,
    4. Flach HZ, et al

    . Callosal lesion predicts future attacks after clinically isolated syndrome. Neurology 2009;73:1837–41

    CrossRef
34. 34.↵
    2. Tintore M,
    3. Rovira A,
    4. Arrambide G, et al

    . Brainstem lesions in clinically isolated syndromes. Neurology 2010;75:1933–38

    CrossRef
35. 35.↵
    2. Minneboo A,
    3. Barkhof F,
    4. Polman CH, et al

    . Infratentorial lesions predict long-term disability in patients with initial findings suggestive of multiple sclerosis. Arch Neurol 2004;61:217–21

    CrossRefPubMedWeb of Science
36. 36.↵
    2. Frischer JM,
    3. Bramow S,
    4. Dal-Bianco A, et al

    . The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009;132:1175–89

    Abstract/FREE Full Text
37. 37.↵
    2. Ashburner J,
    3. Friston KJ

    . Unified segmentation. NeuroImage 2005;26:839–51

    CrossRefPubMedWeb of Science
38. 38.↵
    2. Dale AM,
    3. Fischl B,
    4. Sereno MI

    . Cortical surface-based analysis—I. Segmentation and surface reconstruction. NeuroImage 1999;9:179–94

    CrossRefPubMedWeb of Science
39. 39.↵
    2. Dale AM,
    3. Sereno MI

    . Improved localization of cortical activity by combining EEG and MEG with MRI cortical surface reconstruction–a linear approach. J Cogn Neurosci 1993;5:162–76

    CrossRefPubMedWeb of Science
40. 40.↵
    2. Smith SM,
    3. Jenkinson M,
    4. Woolrich MW, et al

    . Advances in functional and structural MR image analysis and implementation as FSL. NeuroImage 2004;23 Suppl 1:S208–19

    CrossRefPubMedWeb of Science
41. 41.↵
    2. Smith SM,
    3. Zhang Y,
    4. Jenkinson M, et al

    . Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. NeuroImage 2002;17:479–89

    CrossRefPubMedWeb of Science
42. 42.↵
    2. Hagman S,
    3. Raunio M,
    4. Rossi M, et al

    . Disease-associated inflammatory biomarker profiles in blood in different subtypes of multiple sclerosis: prospective clinical and MRI follow-up study. J Neuroimmunol 2011;234:141–47

    CrossRefPubMedWeb of Science
43. 43.↵
    2. Teunissen CE,
    3. Iacobaeus E,
    4. Khademi M, et al

    . Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis. Neurology 2009;72:1322–29

    CrossRef
44. 44.↵
    2. Roosendaal SD,
    3. Bendfeldt K,
    4. Vrenken H, et al

    . Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability. Mult Scler 2011;17:1098–106

    Abstract/FREE Full Text
45. 45.↵
    2. Bergsland N,
    3. Horakova D,
    4. Dwyer MG, et al

    . Subcortical and cortical gray matter atrophy in a large sample of patients with clinically isolated syndrome and early relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol 2012;33:1573–78

    Abstract/FREE Full Text
46. 46.↵
    2. Rocca MA,
    3. Agosta F,
    4. Sormani MP, et al

    . A three-year, multi-parametric MRI study in patients at presentation with CIS. J Neurol 2008;255:683–91

    CrossRefPubMedWeb of Science
47. 47.↵
    2. Hagemeier J,
    3. Weinstock-Guttman B,
    4. Bergsland N, et al

    . Iron deposition on SWI-filtered phase in the subcortical deep gray matter of patients with clinically isolated syndrome may precede structure-specific atrophy. AJNR Am J Neuroradiol 2012;33:1596–601

    Abstract/FREE Full Text
48. 48.↵
    2. Tavazzi E,
    3. Dwyer MG,
    4. Weinstock-Guttman B, et al

    . Quantitative diffusion weighted imaging measures in patients with multiple sclerosis. NeuroImage 2007;36:746–54

    CrossRefPubMedWeb of Science
49. 49.↵
    2. Iannucci G,
    3. Tortorella C,
    4. Rovaris M, et al

    . Prognostic value of MR and magnetization transfer imaging findings in patients with clinically isolated syndromes suggestive of multiple sclerosis at presentation. AJNR Am J Neuroradiol 2000;21:1034–38

    Abstract/FREE Full Text
50. 50.↵
    2. Calabrese M,
    3. Rinaldi F,
    4. Mattisi I, et al

    . The predictive value of gray matter atrophy in clinically isolated syndromes. Neurology 2011;77:257–63

    CrossRef
51. 51.↵
    2. Paolillo A,
    3. Piattella MC,
    4. Pantano P, et al

    . The relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis: a monthly MRI study after triple-dose gadolinium-DTPA. J Neurol 2004;251:432–39

    CrossRefPubMedWeb of Science
52. 52.↵
    2. Henry RG,
    3. Shieh M,
    4. Okuda DT, et al

    . Regional grey matter atrophy in clinically isolated syndromes at presentation. J Neurol Neurosurg Psychiatry 2008;79:1236–44

    Abstract/FREE Full Text
53. 53.↵
    2. Traboulsee A,
    3. Dehmeshki J,
    4. Brex PA, et al

    . Normal-appearing brain tissue MTR histograms in clinically isolated syndromes suggestive of MS. Neurology 2002;59:126–28

    CrossRef
54. 54.↵
    2. Rudick RA,
    3. Lee JC,
    4. Nakamura K, et al

    . Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS. J Neurol Sci 2009;282:106–11

    CrossRefPubMed
55. 55.↵
    2. Sbardella E,
    3. Tomassini V,
    4. Stromillo ML, et al

    . Pronounced focal and diffuse brain damage predicts short-term disease evolution in patients with clinically isolated syndrome suggestive of multiple sclerosis. Mult Scler 2011;17:1432–40

    Abstract/FREE Full Text
56. 56.↵
    2. Raz E,
    3. Cercignani M,
    4. Sbardella E, et al

    . Clinically isolated syndrome suggestive of multiple sclerosis: voxelwise regional investigation of white and gray matter. Radiology 2010;254:227–34

    CrossRefPubMedWeb of Science
57. 57.↵
    2. Ceccarelli A,
    3. Rocca MA,
    4. Perego E, et al

    . Deep grey matter T2 hypo-intensity in patients with paediatric multiple sclerosis. Mult Scler 2011;17:702–07

    Abstract/FREE Full Text
58. 58.↵
    2. Derakhshan M,
    3. Caramanos Z,
    4. Giacomini PS, et al

    . Evaluation of automated techniques for the quantification of grey matter atrophy in patients with multiple sclerosis. NeuroImage 2010;52:1261–67

    CrossRefPubMedWeb of Science
59. 59.↵
    2. Battaglini M,
    3. Jenkinson M,
    4. De Stefano N

    . Evaluating and reducing the impact of white matter lesions on brain volume measurements. Hum Brain Mapp 2012;33:2062–71

    CrossRefPubMedWeb of Science
60. 60.↵
    2. Rovaris M,
    3. Judica E,
    4. Ceccarelli A, et al

    . A 3-year diffusion tensor MRI study of grey matter damage progression during the earliest clinical stage of MS. J Neurol 2008;255:1209–14

    CrossRefPubMedWeb of Science
61. 61.↵
    2. De Stefano N,
    3. Giorgio A,
    4. Battaglini M, et al

    . Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology 2010;74:1868–76

    CrossRef
62. 62.↵
    2. Audoin B,
    3. Ibarrola D,
    4. Malikova I, et al

    . Onset and underpinnings of white matter atrophy at the very early stage of multiple sclerosis–a 2-year longitudinal MRI/MRSI study of corpus callosum. Mult Scler 2007;13:41–51

    Abstract/FREE Full Text
63. 63.↵
    2. Beaulieu C,
    3. Allen PS

    . Determinants of anisotropic water diffusion in nerves. Magn Reson Med 1994;31:394–400

    CrossRefPubMedWeb of Science
64. 64.↵
    2. Yu CS,
    3. Lin FC,
    4. Liu Y, et al

    . Histogram analysis of diffusion measures in clinically isolated syndromes and relapsing-remitting multiple sclerosis. Eur J Radiol 2008;68:328–34

    CrossRefPubMedWeb of Science
65. 65.↵
    2. Caramia F,
    3. Pantano P,
    4. Di Legge S, et al

    . A longitudinal study of MR diffusion changes in normal appearing white matter of patients with early multiple sclerosis. Magn Reson Imaging 2002;20:383–88

    CrossRefPubMedWeb of Science
66. 66.↵
    2. Pagani E,
    3. Filippi M,
    4. Rocca MA, et al

    . A method for obtaining tract-specific diffusion tensor MRI measurements in the presence of disease: application to patients with clinically isolated syndromes suggestive of multiple sclerosis. NeuroImage 2005;26:258–65

    CrossRefPubMedWeb of Science
67. 67.↵
    2. Preziosa P,
    3. Rocca MA,
    4. Mesaros S, et al

    . Intrinsic damage to the major white matter tracts in patients with different clinical phenotypes of multiple sclerosis: a voxelwise diffusion-tensor MR study. Radiology 2011;260:541–50

    CrossRefPubMedWeb of Science
68. 68.↵
    2. Smith SM,
    3. Jenkinson M,
    4. Johansen-Berg H, et al

    . Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data. NeuroImage 2006;31:1487–505

    CrossRefPubMedWeb of Science
69. 69.↵
    2. Raz E,
    3. Cercignani M,
    4. Sbardella E, et al

    . Gray- and white-matter changes 1 year after first clinical episode of multiple sclerosis: MR imaging. Radiology 2010;257:448–54

    CrossRefPubMedWeb of Science
70. 70.↵
    2. Pike GB

    . Pulsed magnetization transfer contrast in gradient echo imaging: a two-pool analytic description of signal response. Magn Reson Med 1996;36:95–103

    CrossRefPubMedWeb of Science
71. 71.↵
    2. Fernando KT,
    3. Tozer DJ,
    4. Miszkiel KA, et al

    . Magnetization transfer histograms in clinically isolated syndromes suggestive of multiple sclerosis. Brain 2005;128:2911–25

    Abstract/FREE Full Text
72. 72.↵
    2. Khalil M,
    3. Enzinger C,
    4. Langkammer C, et al

    . Cognitive impairment in relation to MRI metrics in patients with clinically isolated syndrome. Mult Scler 2011;17:173–80

    Abstract/FREE Full Text
73. 73.↵
    2. Gallo A,
    3. Rovaris M,
    4. Benedetti B, et al

    . A brain magnetization transfer MRI study with a clinical follow up of about four years in patients with clinically isolated syndromes suggestive of multiple sclerosis. J Neurol 2007;254:78–83

    CrossRefPubMedWeb of Science
74. 74.↵
    2. Wattjes MP,
    3. Harzheim M,
    4. Lutterbey GG, et al

    . Axonal damage but no increased glial cell activity in the normal-appearing white matter of patients with clinically isolated syndromes suggestive of multiple sclerosis using high-field magnetic resonance spectroscopy. AJNR Am J Neuroradiol 2007;28:1517–22

    Abstract/FREE Full Text
75. 75.↵
    2. Fernando KT,
    3. McLean MA,
    4. Chard DT, et al

    . Elevated white matter myo-inositol in clinically isolated syndromes suggestive of multiple sclerosis. Brain 2004;127:1361–69

    Abstract/FREE Full Text
76. 76.↵
    2. Wattjes MP,
    3. Harzheim M,
    4. Lutterbey GG, et al

    . Prognostic value of high-field proton magnetic resonance spectroscopy in patients presenting with clinically isolated syndromes suggestive of multiple sclerosis. Neuroradiology 2008;50:123–29

    CrossRefPubMedWeb of Science
77. 77.↵
    2. Pantano P,
    3. Iannetti GD,
    4. Caramia F, et al

    . Cortical motor reorganization after a single clinical attack of multiple sclerosis. Brain 2002;125:1607–15

    Abstract/FREE Full Text
78. 78.↵
    2. Rocca MA,
    3. Colombo B,
    4. Falini A, et al

    . Cortical adaptation in patients with MS: a cross-sectional functional MRI study of disease phenotypes. Lancet Neurol 2005;4:618–26

    CrossRefPubMedWeb of Science
79. 79.↵
    2. Filippi M,
    3. Rocca MA,
    4. Mezzapesa DM, et al

    . Simple and complex movement-associated functional MRI changes in patients at presentation with clinically isolated syndromes suggestive of multiple sclerosis. Hum Brain Mapp 2004;21:108–17

    CrossRefPubMedWeb of Science
80. 80.↵
    2. Rocca MA,
    3. Mezzapesa DM,
    4. Ghezzi A, et al

    . A widespread pattern of cortical activations in patients at presentation with clinically isolated symptoms is associated with evolution to definite multiple sclerosis. AJNR Am J Neuroradiol 2005;26:1136–39

    Abstract/FREE Full Text
81. 81.↵
    2. Audoin B,
    3. Reuter F,
    4. Duong MV, et al

    . Efficiency of cognitive control recruitment in the very early stage of multiple sclerosis: a one-year fMRI follow-up study. Mult Scler 2008;14:786–92

    Abstract/FREE Full Text
82. 82.↵
    2. Rocca MA,
    3. Absinta M,
    4. Moiola L, et al

    . Functional and structural connectivity of the motor network in pediatric and adult-onset relapsing-remitting multiple sclerosis. Radiology 2010;254:541–50

    CrossRefPubMedWeb of Science
83. 83.↵
    2. Liu Y,
    3. Duan Y,
    4. Liang P, et al

    . Baseline brain activity changes in patients with clinically isolated syndrome revealed by resting-state functional MRI. Acta Radiol 2012;53:1073–78

    Abstract/FREE Full Text
84. 84.↵
    2. Liu Y,
    3. Liang P,
    4. Duan Y, et al

    . Brain plasticity in relapsing-remitting multiple sclerosis: evidence from resting-state fMRI. J Neurol Sci 2011;304:127–31

    CrossRefPubMed
85. 85.↵
    2. Varga AW,
    3. Johnson G,
    4. Babb JS, et al

    . White matter hemodynamic abnormalities precede sub-cortical gray matter changes in multiple sclerosis. J Neurol Sci 2009;282:28–33

    CrossRefPubMed
86. 86.↵
    2. Ge Y,
    3. Jensen JH,
    4. Lu H, et al

    . Quantitative assessment of iron accumulation in the deep gray matter of multiple sclerosis by magnetic field correlation imaging. AJNR Am J Neuroradiol 2007;28:1639–44

    Abstract/FREE Full Text
87. 87.↵
    2. Ceccarelli A,
    3. Rocca MA,
    4. Neema M, et al

    . Deep gray matter T2 hypointensity is present in patients with clinically isolated syndromes suggestive of multiple sclerosis. Mult Scler 2010;16:39–44

    Abstract/FREE Full Text
88. 88.↵
    2. Khalil M,
    3. Enzinger C,
    4. Langkammer C, et al

    . Quantitative assessment of brain iron by R(2)* relaxometry in patients with clinically isolated syndrome and relapsing-remitting multiple sclerosis. Mult Scler 2009;15:1048–54

    Abstract/FREE Full Text
89. 89.↵
    2. Khalil M,
    3. Langkammer C,
    4. Ropele S, et al

    . Determinants of brain iron in multiple sclerosis: a quantitative 3T MRI study. Neurology 2011;77:1691–97

    CrossRef
90. 90.↵
    2. Langkammer C,
    3. Liu T,
    4. Khalil M, et al

    . Quantitative susceptibility mapping in multiple sclerosis. Radiology 2013;267:551–59

    CrossRefPubMedWeb of Science
91. 91.↵
    2. Quinn MP,
    3. Gati JS,
    4. Klassen ML, et al

    . Increased deep grey matter iron is present in clinically isolated syndromes. Mult Scler 2014;3:194–202
92. 92.↵
    2. Meca-Lallana JE,
    3. Hernandez-Clares R,
    4. Leon-Hernandez A, et al

    . Plasma exchange for steroid-refractory relapses in multiple sclerosis: an observational, MRI pilot study. Clin Ther 2013;35:474–85

    CrossRefPubMed
93. 93.↵
    2. Kinkel RP,
    3. Dontchev M,
    4. Kollman C, et al

    . Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes: a 10-year follow-up of the controlled high-risk Avonex multiple sclerosis prevention study in ongoing neurological surveillance. Arch Neurol 2012;69:183–90

    CrossRefPubMedWeb of Science
94. 94.↵
    2. Kappos L,
    3. Polman CH,
    4. Freedman MS, et al

    . Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006;67:1242–49

    CrossRef
95. 95.↵
    2. Barkhof F,
    3. Polman CH,
    4. Radue EW, et al

    . Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results. Arch Neurol 2007;64:1292–98

    CrossRefPubMedWeb of Science
96. 96.↵
    2. Kinkel RP,
    3. Simon JH,
    4. Baron B

    . Bimonthly cranial MRI activity following an isolated monosymptomatic demyelinating syndrome: potential outcome measures for future multiple sclerosis ‘prevention’ trials. Mult Scler 1999;5:307–12

    Abstract/FREE Full Text
97. 97.↵
    2. Deoni SC,
    3. Rutt BK,
    4. Jones DK

    . Investigating exchange and multicomponent relaxation in fully balanced steady-state free precession imaging. J Magn Reson Imaging 2008;27:1421–29

    CrossRefPubMed
98. 98.↵
    2. Kitzler HH,
    3. Su J,
    4. Zeineh M, et al

    . Deficient MWF mapping in multiple sclerosis using 3D whole-brain multi-component relaxation MRI. NeuroImage 2012;59:2670–77

    CrossRefPubMed